

THE LANCET

Infectious Diseases

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

This online publication has been corrected. The corrected version first appeared at [thelancet.com/infection](https://www.thelancet.com/infection) on November 22, 2021.

Supplement to: Jentsch PC, Anand M, Bauch CT. Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study. *Lancet Infect Dis* 2021; published online March 31. [https://doi.org/10.1016/S1473-3099\(21\)00057-8](https://doi.org/10.1016/S1473-3099(21)00057-8).

Supplementary Appendix: Prioritizing COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study

Peter C. Jentsch^{1,2}, Madhur Anand¹, and Chris T. Bauch^{2,*}

¹Department of Applied Mathematics, University of Waterloo, Waterloo, Ontario, Canada; ²School of Environmental Sciences, University of Guelph, Guelph, Ontario, Canada; *cbauch@uwaterloo.ca

Supplementary Methods

Model Equations. Transmission dynamics are given by an SEPAIR model, modified to take population adherence to NPIs and school/workplace closure into account, and divided into age classes $i \in [1, 16]$, where each age class contains a 5 year cohort, except for the oldest age group which comprises the ages 75 and over. The model equations are:

$$\frac{dS_i^1}{dt} = -r\rho_i \left[1 + s \sin \left(\frac{2\pi}{365}(t - \phi) - \frac{\pi}{2} \right) \right] S_i^1 \sum_{j=1}^{16} C_{ij}(t) \left(\frac{I_{s_j} + I_{a_j} + P_j}{N_j} \right) - \tau S_i^1 \quad [1]$$

$$\frac{dS_i^2}{dt} = -r\rho_i \left[1 + s \sin \left(\frac{2\pi}{365}(t - \phi) - \frac{\pi}{2} \right) \right] S_i^2 \sum_{j=1}^{16} C_{ij}(t) \left(\frac{I_{s_j} + I_{a_j} + P_j}{N_j} \right) - \tau S_i^2 \quad [2]$$

$$\frac{dE_i}{dt} = r_i \left[1 + s \sin \left(\frac{2\pi}{365}(t - \phi) - \frac{\pi}{2} \right) \right] (S_i^1 + S_i^2) \sum_{j=1}^{16} C_{ij}(t) \left(\frac{I_{s_j} + I_{a_j} + P_j}{N_j} \right) - \sigma_0 E_i + \tau(S_i^1 + S_i^2) \quad [3]$$

$$\frac{dP_i}{dt} = \sigma_0 E_i - \sigma_1 P_i \quad [4]$$

$$\frac{dI_{a_i}}{dt} = \eta\sigma_1 P_i - \gamma_a I_{a_i} \quad [5]$$

$$\frac{dI_{s_i}}{dt} = (1 - \eta)\sigma_1 P_i - \gamma_s I_{s_i} \quad [6]$$

$$\frac{dR_i}{dt} = \gamma_a I_{a_i} + \gamma_s I_{s_i} \quad [7]$$

$$\frac{dD_i}{dt} = \Omega(D(t)) \quad [8]$$

Parameter values are defined in Table S1. The vaccination dynamics are an impulsive process applied each day, described below. S_i^1 is the number of unvaccinated susceptible individuals in age group i , and S_i^2 is the number of susceptible individuals in age group i who have received a standard two dose course of vaccination but were not immunized. $E_i(t)$ is the number of exposed but not yet infectious individuals in age group i (i.e., individuals in the latent period). $I_{a_i}(t)$ is the number of asymptomatic infectious individuals in age group i and $I_{s_i}(t)$ is the number of symptomatic infectious individuals in age group i . $R_i(t)$ is the number of Removed (recovered, vaccinated, and deceased) individuals in compartment i .

The variable $D(t) \in [0, 1]$ in the model equation $dD(t)/dt = \Omega(D(t))$ represents the public health authority's reaction to the prevalence of ascertained cases and it evolves according to:

$$\Omega(D(t)) = \begin{cases} k_1(1 - D(t)) & \sum_{i=1}^{16} \alpha_i (I_{a_i} + I_{s_i}) > T \\ -k_2 D(t) & \sum_{i=1}^{16} \alpha_i (I_{a_i} + I_{s_i}) \leq T \end{cases} \quad [9]$$

This represents closure being triggered when ascertained cases exceed a threshold T , and being lifted when cases drop below that threshold again.

The proportion x of individuals who practice NPIs such as mask wearing, handwashing, and physical distancing, starts off at $x(0) = 0.01$ and evolves as:

$$\frac{dx}{dt} = \kappa x(1 - x) \left(\frac{\sum_{i=1}^{16} \alpha_i (I_{a_i} + I_{s_i})}{\sum_{i=1}^{16} N_i} - cx \right) + p_{ul}(1 - 2x) \quad [10]$$

where κ is the social learning rate, c is the incentive to not practice NPIs, and α_i is the fraction of total cases ($I_a + I_s$) that are reported, also known as the ascertainment rate. The p_{ul} term is a phenomenological term that represents

the effects of social heterogeneity and influence from external populations that prevents the system from remaining arbitrarily close to $x = 0$ or $x = 1$ for unrealistic periods of time. These equations describe a population where individual sample other individuals at some time rate and switch between adherence and non-adherence to NPIs with a probability proportional to the expected gain in utility $\sum_{i=1}^{16} \alpha_i (I_{a_i} + I_{s_i}) - cx$. We refer the reader to existing literature for details on the derivation of this equation (1-5).

$C_{ij}(t, x)$ is the average number of contacts per day and consists of contacts at workplaces, schools, households, and other locations, which vary depending on government shutdown policies as well as individual adherence to NPIs like physical distancing and mask use:

$$C_{ij}(t, x) = C_{ij}^W(t) + C_{ij}^S(t) + (1 - \epsilon_P x)(\bar{C}_{ij}^O + \bar{C}_{ij}^H) \quad [11]$$

The contacts in each of the aforementioned places can vary as follows. At workplaces, which can be closed by public health authorities:

$$C_{ij}^W(t) = \begin{cases} (1 - \epsilon_W)\bar{C}_{ij}^W & t - t_{delay} > t_{close}, t - t_{delay} < t_{open}^w \\ \bar{C}_{ij}^W & t - t_{delay} < t_{close}^w \\ (1 - D(t)(1 - \epsilon_W))\bar{C}_{ij}^W & t - t_{delay} > t_{open}^w \end{cases} \quad [12]$$

where \bar{C}_{ij}^W is the normal (non-pandemic) number of contact-hours per day between individuals of age i and j at the workplace (6); $\bar{C}_{ij}^W(1 - D(t)\epsilon_P)$ is the reduced rate under workplace closure efficacy $0 < \epsilon_W < 1$ and closure level $D(t)$; and t_{delay} represents the delay between the decision to adopt NPIs and their impact on transmission (7). Lower than perfect efficacy may stem either from occasional use of workplace for critical needs or non-authorized access, workplaces that remain open because they provide essential services, etc. t_{close}^W and t_{open}^W are the times of closing and re-opening workplaces, respectively. Similarly, for schools we have:

$$C_{ij}^S(t) = \begin{cases} 0 & t - t_{delay} > t_{close}^s, t - t_{delay} < t_{open}^s \\ \bar{C}_{ij}^S & t - t_{delay} < t_{close}^s \\ (1 - D(t))\bar{C}_{ij}^S & t - t_{delay} > t_{open}^s \end{cases} \quad [13]$$

All other places of exposure are governed by social processes with imperfect ability of public health authorities to enforce mandates, and hence are governed by voluntary population adherence to NPIs such as mask use and physical distancing as per the $\epsilon_P x(t)$ term in the equation, where ϵ_P is efficacy of individual adoption of NPIs. In principle, contact hours spent at home should increase as workplaces and schools are closed, but we assume that infection probabilities will saturate rapidly with contact hours in the home. Each of the conditional functions in equations (12,13), are represented in the model as a smoothed step function with a steep slope, and we restrict them between 0 and 1 if the smoothing process would cause the closure level $D(t)$ to exceed 1.0. Finally, our interventions (school and workplace shutdown) do not distinguish between preventing contacts in home versus other locations. We assume the same efficacy of NPIs in home as in "other" locations. On one hand, individuals are less likely to use NPIs at home. On the other hand, contacts at home are repeated and thus there is a saturating effect that can somewhat reduce the infection risk, compared to the diversity of contacts experienced in the general community. Additionally, our case notifications are not broken down by the location of infection and thus we have limited ability to parameterize two difference NPI efficacy in home and "other" locations. As a result, we assume the same efficacy in both settings.

Vaccination process. Each day, the total number of individuals vaccinated is equal to $\sum_{i=1}^{16} \phi \frac{S_i(t)}{N_i}$, and the number of individuals immunized against transmission of the virus is $\sum_{i=1}^{16} v_{T_i} \frac{S_i(t)}{N_i - V_i}$ on account of imperfect vaccination. The factor $\frac{S_i(t)}{N_i - V_i}$ represents vaccination of each person with equal probability, so the probability of vaccinating a susceptible person decreases with the fraction of susceptible individuals out of the non-vaccinated people. If there are less than ϕ_i individuals in group S_i^1 , then the remainder of the vaccine is spread evenly among the remaining non-vaccinated groups. Individuals who are vaccinated but not immunized due to imperfect efficacy are moved to the corresponding S_i^2 . We assume that a course of vaccination will not be administered to a person more than twice.

The fraction of people who are vaccinated against disease but not against transmissibility is $v_{D_i} - v_{T_i}$. We assume this fraction of people is still able to transmit the disease normally, and therefore we account for them by reducing the mortality rate (see Supp. Mortality computation).

Differences between parameters in the first and second wave. To account for the differences in social response, to the first and second waves of the infection, we assume that the social dynamics variables κ (the social learning rate), and c (the incentive not to distance). We assume that these variables are functions of time, which transition between two values at a time $t_{switch} = 160$ days after the beginning of the pandemic.

$$\kappa = \kappa(t) = \kappa_2 \left(\frac{\tanh(k_s(t - t_{switch})) + 1}{2} \right) + \kappa_1 \left(1 - \frac{\tanh(k_s(t - t_{switch})) + 1}{2} \right) \quad [14]$$

$$c = c(t) = c_2 \left(\frac{\tanh(k_s(t - t_{switch})) + 1}{2} \right) + c_1 \left(1 - \frac{\tanh(k_s(t - t_{switch})) + 1}{2} \right) \quad [15]$$

73 We chose the rate of switch, $k_s = 0.05$ to take 2 - 4 weeks.

74 **Case under-ascertainment.** Case under-ascertainment of the i th age group is represented by the following function:

$$\alpha_i(t) = \begin{cases} \alpha_{i,2} & t > t_{switch} \\ \alpha_{i,1} \left(\frac{t_{switch} - t}{t_{switch}} \right) & t \leq t_{switch} \end{cases} \quad [16]$$

76 where where $\alpha_{1,1}, \alpha_{2,1}, \alpha_{3,1}$ corresponds to the ascertainment in the age groups (0, 20), (20, 60), > 60 at $t = 0$,
77 respectively. We assume that the ascertainment rises to a value of $\alpha_{1,2}, \alpha_{2,2}, \alpha_{3,2}$ in the age groups (0, 20), (20, 60), > 60
78 respectively, at $t = t_{switch}$, denoting the increase in ascertainment throughout the first wave and into the second wave.
79 We multiply the infections in each age group i at time t by the corresponding $\alpha_i(t)$ after the simulation is finished.

80 **Baseline transmission rate.** We can compute r as a function of the next-generation matrix, $M = -\Theta\Sigma^{-1}$ (8), where
81 Θ and Σ are defined as in equations 17,18, and so M is a function of $R_0, \sigma_0, \sigma_1, \gamma_a, \gamma_s, \eta, C(t)$, and N . These matrices
82 come from the rate at which infected individuals enter and leave the infection compartments when the system is
83 linearized about the $I_a = 0, I_s = 0, P = 0$ equilibrium. The basic reproduction ratio, R_0 , of the infection is the
84 spectral radius of M , written $\rho(M)$. We can pull r out of this expression, giving a new matrix \hat{M} , and write r in
85 terms of the other parameters: $r = \frac{R_0}{\rho(\hat{M})}$.

$$\Theta = \begin{bmatrix} 0 & \dots & 0 & \frac{rC_{1,1}(0)N_1}{N_1} & \dots & \frac{rC_{1,n}(0)N_1}{N_n} & \frac{rC_{1,1}(0)N_1}{N_1} & \dots & \frac{rC_{1,n}(0)N_1}{N_n} & \frac{rC_{1,1}(0)N_1}{N_1} & \dots & \frac{rC_{1,n}(0)N_1}{N_n} \\ \vdots & \ddots & \vdots & \vdots & \vdots & \vdots & \vdots & \ddots & \vdots & \vdots & \ddots & \vdots \\ 0 & \dots & 0 & \frac{rC_{1,n}(0)N_n}{N_1} & \dots & \frac{rC_{n,n}(0)N_n}{N_n} & \frac{rC_{1,1}(0)N_n}{N_1} & \dots & \frac{rC_{n,n}(0)N_n}{N_n} & \frac{rC_{1,n}(0)N_n}{N_1} & \dots & \frac{rC_{n,n}(0)N_n}{N_n} \\ 0 & \dots & 0 & 0 & \dots & 0 & 0 & \dots & 0 & 0 & \dots & 0 \\ \vdots & \ddots & \vdots & \vdots & \vdots & \vdots & \vdots & \ddots & \vdots & \vdots & \ddots & \vdots \\ 0 & \dots & 0 & 0 & \dots & 0 & 0 & \dots & 0 & 0 & \dots & 0 \\ 0 & \dots & 0 & 0 & \dots & 0 & 0 & \dots & 0 & 0 & \dots & 0 \\ \vdots & \ddots & \vdots & \vdots & \vdots & \vdots & \vdots & \ddots & \vdots & \vdots & \ddots & \vdots \\ 0 & \dots & 0 & 0 & \dots & 0 & 0 & \dots & 0 & 0 & \dots & 0 \end{bmatrix} \quad [17]$$

$$\Sigma = \begin{bmatrix} -\sigma_0 & \dots & 0 & 0 & \dots & 0 & 0 & \dots & 0 & 0 & \dots & 0 \\ \vdots & \ddots & \vdots & \vdots & \vdots & \vdots & \vdots & \ddots & \vdots & \vdots & \ddots & \vdots \\ 0 & -\sigma_0 & \vdots & \vdots & \vdots & \vdots & 0 & \dots & 0 & 0 & \dots & 0 \\ 0 & \dots & -\sigma_0 & 0 & \dots & 0 & 0 & \dots & 0 & 0 & \dots & 0 \\ \vdots & \ddots & \vdots & -\sigma_1 & \dots & \vdots & \vdots & \ddots & \vdots & \vdots & \ddots & \vdots \\ \vdots & \ddots & \vdots & \vdots & \vdots & -\sigma_1 & \vdots & \ddots & \vdots & \vdots & \ddots & \vdots \\ 0 & \dots & 0 & 0 & \dots & -\sigma_1 & 0 & \dots & 0 & 0 & \dots & 0 \\ 0 & \dots & 0 & \eta\sigma_1 & \dots & 0 & -\gamma_a & \dots & 0 & 0 & \dots & 0 \\ \vdots & \ddots & \vdots & \vdots & \vdots & \vdots & \vdots & \ddots & \vdots & \vdots & \ddots & \vdots \\ \vdots & \ddots & \vdots & \vdots & \vdots & \eta\sigma_1 & \vdots & \ddots & \vdots & \vdots & \ddots & \vdots \\ 0 & \dots & 0 & 0 & \dots & \eta\sigma_1 & 0 & \dots & -\gamma_a & 0 & \dots & 0 \\ 0 & \dots & 0 & (1-\eta)\sigma_1 & \dots & 0 & 0 & \dots & -\gamma_s & \dots & \dots & 0 \\ \vdots & \ddots & \vdots & \vdots & \vdots & \vdots & \vdots & \ddots & \vdots & \vdots & \ddots & \vdots \\ \vdots & \ddots & \vdots & \vdots & \vdots & (1-\eta)\sigma_1 & \vdots & \ddots & \vdots & \vdots & \ddots & \vdots \\ 0 & \dots & 0 & 0 & \dots & (1-\eta)\sigma_1 & 0 & \dots & 0 & 0 & \dots & -\gamma_s \\ & & & & & & (1-\eta)\sigma_1 & & & & & -\gamma_s \end{bmatrix} \quad [18]$$

90 **Disease progression parameters.** Transition rates for the duration of the asymptomatic infectious period and the
91 proportion of symptomatic cases were obtained from COVID-19 epidemiological literature (9–11). We computed the
92 mortality due to COVID-19 by applying the case fatality rate obtained from (12), interpolated to 16 age groups.

93 **Initial conditions.** The point $t = 0$ was chosen to be the day at which the province of Ontario recorded more than 50
94 cases, March 10th 2020, to reduce the effects of stochasticity in the early case counts. Let the number of observed
95 cases of COVID-19 in age group i on March 10th 2020 be ω_i . We use the age distribution of ω_i to determine the
96 age distribution for $I_a(t) + I_s(t)$. The true number of cases that day is ω_i/α_i , where α_i is the ascertainment rate
97 of cases in group i . Since we do not know the actual number of active cases, $I_{a_i}(t) + I_{s_i}(t)$ at $t = 0$, we assume
98 the number of active cases is equal to the true number of incident cases multiplied by a constant I_0 , which is also
99 treated as a model variable to be fitted. Therefore, $I_{s_i}(0) = \eta I_0 \frac{\omega_i}{\alpha_i}$ and $I_{a_i}(0) = (1 - \eta) I_0 \frac{\omega_i}{\alpha_i}$. Similarly, we assumed
100 that the numbers of presymptomatic and exposed cases at $t = 0$ are proportional to the number of ascertained
101 incident cases in each age group, ω_i . We fit the variables P_0 and E_0 so that $P(0) = P_0 \frac{\omega_i}{\alpha_i}$ and $E(0) = E_0 \frac{\omega_i}{\alpha_i}$.
102 We assumed that $S_i^1(0) = N_i - (I_a(0) + I_s(0) + E(0) + P(0))$, so the total number of susceptible, unvaccinated
103 individuals $\sum_{i=1}^{16} S_i^1(0)$ is the population of the region (minus the number who begin in the infected compartments),
104 and $S_i^2(0) = 0, E_i(0) = 0, R_i(0) = 0$ for all i . Lastly, we assumed that at $t = 0$, only 1% of individuals are physical
105 distancing, so $x(0) = 0.01$, and that $D(0) = 0$.

Particle filtering. We calibrated the model with data from Ontario, Canada. Since the workplace closure opening and
closing rates, k_1 and k_2 , are not coupled with the model, we fit a step function of the form

$$f(t) = \epsilon_W \left(\tanh k_1(t - t_{close}^W) - \tanh k_2(t - t_{close}^W) \right)$$

106 to the "workplaces_percent_change_from_baseline" field of the Google mobility data (13) for the province. We
107 applied a particle filtering approach using intervals around selected parameters. Intervals used for sampling appear in
108 Table S1. We fit the 7-day moving average of incident cases on each day across all age groups to the number of cases
109 registered by Public Health Ontario on that day (14), and also the total number of cases at the end of the fitting
110 window for each age group. The decrease in contact-hours due to social distancing, $x(t)$, was fit to the decrease in
111 the "Retail and Recreation" hours recorded by Google mobility (13). The 1.1 % (0.8 %, 1.3 %) of Ontario residents
112 seropositive for COVID-19 in June 2021 was also used as a fitting criterion (15). The posterior distribution of the
113 parameters was estimated with the approximate Bayesian computation scheme described in (16), with uniform priors
114 and 200 particles, using the KissABC (17) library for the Julia language. The acceptance threshold was chosen to
115 given acceptable variation and evaluation time.

116 **Vaccination refusal dynamics.** In an extension to the model explored the dynamics of the model with the added
117 complication of vaccine refusal. We introduce a variable $y(t)$ to represent that fraction of the population willing to be
118 vaccinated for the virus, governed by imitation dynamics similar to the social distancing equation 10. We add the
119 following equation 19 to the rest of the model equations (1, 4).

$$\frac{dy}{dt} = \kappa_{vac} y(1 - y) \left(\frac{\sum_{i=1}^{16} \alpha_i (I_{a_i} + I_{s_i})}{\sum_{i=1}^{16} N_i} - c_{vac} \right) \quad [19]$$

121 In the above equation, the vaccination decisions of the population are governed by a payoff function, where c_{vac} is
122 the payoff not to vaccinate, and the payoff to vaccinate is proportional to current the number of ascertained active
123 infections. The initial condition for this variable, y_0 is assumed to be 0.67 from (18).

124 The population in age group i that refuses to be vaccinated is $N_i(1 - y(t))$. We implement this mechanic in the
125 model by assuming that the number of people vaccinated each day in age group i , ψ_i is unchanged, except that the
126 compartment $S_{v_i}^1$ is considered to be empty when $N_i(1 - y(t))$ people remain.

127 **Model extension for vaccine efficacy against disease only.** We conducted the sensitivity analysis scenario distin-
128 guishing vaccine efficacy against disease only versus vaccine efficacy against both infectivity and disease by adjusting
129 the case fatality rates according to vaccine coverage in the population and assumed efficacies. The adjustment factor
130 is determined by the relative sizes of $S_1(t)$ and $S_2(t)$. Let $\xi_1(S_1(t)) = \xi S_1(t)$ be the rate at which individuals in $S_1(t)$
131 are infected, and similarly $\xi_2 = \xi S_2(t)$ the rate at which individuals in $S_2(t)$ are infected. Let $S_3(t)$ be the number of
132 people at t who are immunized but still able to transmit the virus, and $\xi_3 = \xi S_3(t)$. We also assume that

$$\frac{\xi_1(t)}{\xi_3(t)} = \frac{1 - v_{D_i}}{v_{D_i} - v_{T_i}} \quad [20]$$

134 which applies given that the timescale of infection in individuals is fast compared to the whole duration of the
135 pandemic. The proportion of unvaccinated people who are infected at t is $\frac{\xi_1(t)}{\xi_1(t) + \xi_2(t) + \xi_3(t)}$, and the fraction of

136 vaccinated but not immunized people infected at t is $\frac{\xi_2(t)}{\xi_1(t)+\xi_2(t)+\xi_3(t)}$. From equation 20, and the model equations, we
137 can adjust the probability that a given person who is infected also dies at time t as

138 Adjusted mortality at t for age group $i = \frac{S_{1_i}(t) + S_{2_i}(t)}{S_{1_i}(t) + S_{2_i}(t) \frac{1-v_{T_i}}{1-v_{D_i}}} \times \text{Cases at } t \times \text{measured CFR} \quad [21]$

Table S1. Parameter definitions, values, particle filtering ranges, and sources.

Parameter	Meaning	Value [Range]	Source
N_i	Population in age group i	0 – 4: 790169; 5 – 9: 789190 10 – 14: 790803; 15 – 19: 887072 20 – 24: 1003052; 25 – 29: 1015105 30 – 34: 1009090; 35 – 39: 969949 40 – 44: 926440; 45 – 49: 938990 50 – 54: 1027557; 55 – 59: 10416495 60 – 64: 892016; 65 – 69: 741824 70 – 74: 557203; 75+: 204431	(19), interpolated
μ_i	COVID-19 case fatality rate in age group i	0 – 4: 0.002; 5 – 9: 0.001 10 – 14: 0.0005; 15 – 19: 0.0005 20 – 24: 0.0010; 25 – 29: 0.002 30 – 34: 0.0031; 35 – 39: 0.0048 40 – 44: 0.0078; 45 – 49: 0.0135 50 – 54: 0.0253; 55 – 59: 0.0455 60 – 64: 0.0784; 65 – 69: 0.1378 70 – 74: 0.2623; 75+: 0.5815	(12), interpolated
C_{ij}	contact rate between class i and j	see Supp. Methods	(20)
R_0	basic reproduction rate of infection	calibrated, [1.5, 2.5]	(13, 14, 21)
r	probability of transmission per contact	derived from next generation matrix	(8)
σ_0	inverse of latent period for exposed individuals	calibrated, [0.3, 2.0]	(9–11, 13, 14)
σ_1	inverse of latent period for presymptomatic individuals	calibrated, [0.3, 2.0]	(9–11, 13, 14)
γ_a	inverse of infectious period for asymptomatic individuals	0.25/day	(9–11)
γ_s	inverse of infectious period for symptomatic individuals	calibrated, [0.0, 0.05]	(9–11, 13, 14)
$\alpha_{1,1}$	Ascertainment rate of class i in the first wave (before t_{switch})	calibrated, [0.01, 1.0]	see Supp. Methods
$\alpha_{1,2}$	Ascertainment rate of class i in the first wave (before t_{switch})	calibrated, [0.01, 1.0]	see Supp. Methods
$\alpha_{1,3}$	Ascertainment rate of class i in the first wave (before t_{switch})	calibrated, [0.2, 1.0]	see Supp. Methods
$\alpha_{2,1}$	Ascertainment rate of class i in the second wave (after t_{switch})	calibrated, [0.01, 1.0]	see Supp. Methods
$\alpha_{2,2}$	Ascertainment rate of class i in the second wave (after t_{switch})	calibrated, [0.01, 1.0]	see Supp. Methods
$\alpha_{2,3}$	Ascertainment rate of class i in the second wave (after t_{switch})	calibrated, [0.2, 1.0]	see Supp. Methods
ρ_1	Age-specific susceptibility modifier, ages 0-20	calibrated, [0.25, 3.0]	see Supp. Methods
ρ_2	Age-specific susceptibility modifier, ages 20-60	calibrated, [0.25, 3.0]	see Supp. Methods
ρ_3	Age-specific susceptibility modifier, ages 60+	calibrated, [0.25, 3.0]	see Supp. Methods
η	fraction of symptomatic infections	0.15	(22)
ϵ_P	efficacy of physical distancing	calibrated, [0.3, 0.9]	(13, 14)
κ	social learning rate	calibrated, [1000, 16000]	(13, 14)
s	seasonality	calibrated, [-0.3, 0.3]	(13, 14)
ϕ	seasonality phase	-30 days	see Supp. Methods
v_{T_i}	Vaccine efficacy against transmissibility and disease for individuals in group i	75%	(23)
v_{D_i}	Vaccine efficacy against disease only for individuals in group i	75%	(23)
I_0	Initial ratio of active cases to incident cases	calibrated, [1, 10]	(13, 14)
P_0	Initial ratio of presymptomatic cases to incident cases	calibrated, [1, 10]	
E_0	Initial ratio of exposed cases to incident cases	calibrated, [1, 10]	
ψ_i	Number of vaccines allocated for individuals in group i each day	varied by scenario	
T	Threshold in active reported cases for school/workplace closure	varied by scenario	
k_1	Workplace shutdown rate	0.31432	fitted, see Supp. Methods
k_2	Workplace opening rate	0.0056	fitted, see Supp. Methods
c	Incentive not to distance	calibrated, [0.0, 0.5]	(13, 14)
p_{ul}	social heterogeneity parameter	calibrated, [0.00, 0.05]	(13, 14)
t_{close}^s	School shutdown date	March 14th, 2020	(24)
t_{open}^s	School opening date	September 8th, 2020	(25)
t_{close}^w	Work shutdown date	March 17th, 2020	(26)
t_{open}^w	Work opening date	June 12th, 2020	(26)
ϵ_w	Work shutdown effectiveness	0.86	fitted, see Supp. Methods
t_{switch}	Beginning of second wave	160 days	see Supp. Methods
t_{delay}	Delay in impact of interventions on transmission	28 days	(7)
k_s	Rate of change from first to second wave	0.05	see Supp. Methods
κ_{vac}	Social learning rate of vaccination	[3e5, 20e5]	fitted, see Supp. Methods
c_{vac}	Incentive not to vaccinate	[1.0e - 9, 15e - 9]	fitted, see Supp. Methods




Fig. S1. Posterior distributions on inferred non-age structured model parameters for baseline model.Posteriors are composed of 200 candidate parameter sets from the particle filtering, the model was evaluated at these points for all future runs.




Fig. S2. Posterior distributions on inferred age-specific susceptibility modifier parameter ρ_i for baseline model. Three age-specific susceptibility parameters shown here, ρ_1, ρ_2, ρ_3 , were also inferred from particle filtering on the case and mobility data, corresponding to the age brackets 0-20, 20-60, 60+.




Fig. S3. Posterior distributions on inferred age-specific ascertainment rate over time for baseline model. Time dependent ascertainment rates inferred from the data, corresponding to the fraction of actual cases detected by the Ontario testing system.




Fig. S4. Empirical data of cumulative infections due to COVID-19 by age and model posterior predictions. The age-specific total cases at the end of the fitting window, were used to calibrate the model, in an age dependent way. We used only three parameters to capture age specific effects and therefore trade-off some accuracy in the youngest and oldest age groups.




Fig. S5. Average of model posterior population seropositivity over time, compared to empirical data. Total seroprevalence in Ontario was assessed during the month of June. We used this value to calibrate the model further.

Contact-based vaccination strategy




Fig. S6. Age distribution of vaccination under the contact-based strategy. This strategy vaccinates proportionally to the leading eigenvector of the full contact matrix, $C(0)$, to vaccinate people who will, approximately, produce the most secondary infections in a linearized regime.




Fig. S7. Social and epidemic dynamics for early vaccine availability and high vaccination rate. (a) Ascertained incident COVID-19 cases, (b) proportion x of the population practicing NPIs, (c) intensity of school and workplace closure, (d) percentage of population with natural or vaccine-derived immunity versus time. $T = 200\%$, $\psi_0 = 1.5\%$ per week, vaccine available in January 2021. Other parameters are in Table S1.




Fig. S8. Social and epidemic dynamics for late vaccine availability and high vaccination rate. (a) Ascertained incident COVID-19 cases, (b) proportion x of the population practicing NPIs, (c) Intensity of school and workplace closure, (d) percentage of population with natural or vaccine-derived immunity versus time. $T = 200\%$, $\psi_0 = 1.5\%$ per week, vaccine available in September 2021. Other parameters are in Table S1.




Fig. S9. Social and epidemic dynamics for late vaccine availability and low vaccination rate. (a) Ascertained incident COVID-19 cases, (b) proportion x of the population practicing NPIs, (c) Intensity of school and workplace closure, (d) percentage of population with natural or vaccine-derived immunity versus time. $T = 200\%$, $\psi_0 = 0.5\%$ per week, vaccine available in September 2021. Other parameters are in Table S1.




Fig. S10. Mortality reductions under various values of T and ψ_0 , early vaccine availability. Violin plots of the percent reduction in mortality under the four vaccine strategies, relative to no vaccination, as a function of the vaccination rate ψ_0 , for January 2021 availability. Horizontal lines represent median values of posterior model projections. Other parameter values in Table S1. Percentage reductions are relative to no vaccination. Projected number of deaths in the absence of vaccination were 35597.2 (CI: 57465.9,19507.9); 48518.8 (CI: 86853.9,28335.7), 61339.1 (CI: 106623.0,34613.5), 72007.3 (CI: 121754.0,40483.4); 80707.6 (CI: 126732.0,47755.4) after January 1, 2021, for $T=50\%$, 100% , 150% , 200% , and 250% , respectively.




Fig. S11. Mortality reductions under various values of T and ψ_0 , late vaccine availability. Violin plots of the percent reduction in mortality under the four vaccine strategies, relative to no vaccination, as a function of the vaccination rate ψ_0 , for September 2021 availability. Horizontal lines represent median values of posterior model projections. Other parameter values in Table S1. Percentage reductions are relative to no vaccination. Projected number of deaths in the absence of vaccination were 25478.8 (CI: 45679.0,13006.7); 39149.6 (CI: 73917.1,20290.9); 50775.1 (CI: 95451.2,25980.9); 60250.7 (CI: 108361.0,30721.9); 68594.0 (CI: 107157.0,36063.6) after September 1, 2021 for $T=50\%$, 100% , 150% , 200% , and 250% , respectively.




Fig. S12. A higher level of natural immunity increases the relative advantage of transmission-interrupting strategies. Median and standard deviation of the percent reduction in mortality under the four vaccine strategies, relative to no vaccination, as a function of the vaccination start date and percent recovered at that time, for (a) $\phi_0 = 1.0\%$ vaccinated per week and (b) $\phi_0 = 2.5\%$ vaccinated per week. Shutdown threshold $T = 200\%$, and other parameter values in Appendix, Table S1.




Fig. S13. Sensitivity analysis exploring a range of vaccine efficacy values, for vaccination rate $\phi_0 = 2.5\%$ per week. Subpanels are parameter planes for January and September availability showing the vaccination strategy that reduces COVID-19 mortality the most as a function of vaccine efficacy in 60+ year-olds versus vaccine efficacy in other age groups. Other parameter values as in Table S1.




Fig. S14. Sensitivity analysis exploring impact of vaccinating behaviour dynamics. $\phi_0 = 2.5\%$ per week, $T = 200\%$. Subpanels are parameter planes for January and September availability showing the vaccination strategy that reduces COVID-19 mortality the most as a function of vaccine social learning rate k_{vacc} and vaccine cost parameter c_{vacc} . Other parameter values as in Table S1.




Fig. S15. Epidemic dynamics and social dynamics for both NPI adherence and vaccinating behaviour, when vaccine cost is small, $c_{vac} = 1.1 \times 10^{-4}$. (a) Ascertained incident COVID-19 cases, (b) proportion x of the population practicing NPIs, (c) Intensity of school and workplace closure, (d) percentage of population with natural or vaccine-derived immunity versus time. $T = 200\%$, $\psi_0 = 1.0\%$ per week (maximum rate in absence of vaccine refusal), vaccine available in September 2021, $\kappa_{vac} = 50/\text{day}$. Other parameters are in Table S1.




Fig. S16. Epidemic dynamics and social dynamics for both NPI adherence and vaccinating behaviour, when vaccine cost is moderate, $c_{vac} = 2.9 \times 10^{-4}$. (a) Ascertained incident COVID-19 cases, (b) proportion x of the population practicing NPIs, (c) Intensity of school and workplace closure, (d) percentage of population with natural or vaccine-derived immunity versus time. $T = 200\%$, $\psi_0 = 1.0\%$ per week (maximum rate in absence of vaccine refusal), vaccine available in September 2021, $\kappa_{vac} = 50/\text{day}$. Other parameters are in Table S1.




Fig. S17. Epidemic dynamics and social dynamics for both NPI adherence and vaccinating behaviour, when vaccine cost is high, $c_{vac} = 3.8 \times 10^{-4}$. (a) Ascertained incident COVID-19 cases, (b) proportion x of the population practicing NPIs, (c) Intensity of school and workplace closure, (d) percentage of population with natural or vaccine-derived immunity versus time. $T = 200\%$, $\psi_0 = 1.0\%$ per week (maximum rate in absence of vaccine refusal), vaccine available in September 2021, $\kappa_{vac} = 50/\text{day}$. Other parameters are in Table S1.




Fig. S18. Sensitivity analysis for the scenario where $R_0 = 2.5$ for December 2020 onward. Subpanels are (left) parameter planes for January and September availability showing the vaccination strategy that prevents the most COVID-19 deaths as a function of T and ψ_0 , and (right) percentage reductions in mortality. Other parameter values are as in Table S1.




Fig. S19. Sensitivity analysis for the scenario of 30% heightened ascertainment across all ages from December 2020 onward. Subpanels are parameter planes for January and September availability showing the vaccination strategy that reduces COVID-19 mortality the most as a function of T and ψ_0 (left) and the corresponding posterior parameter distributions for the refitted parameters (right). Other parameter values as in Table S1.




Fig. S20. Sensitivity analysis for the scenario of 30% reduced ascertainment across all ages from December 2020 onward. Subpanels are parameter planes for January and September availability showing the vaccination strategy that reduces COVID-19 mortality the most as a function of T and ψ_0 (left) and the corresponding posterior parameter distributions for the refitted parameters (right). Other parameter values as in Table S1.




Fig. S21. Sensitivity analysis for the scenario of four times the baseline social learning rate from December 2020 onward. Subpanels are parameter planes for January and September availability showing the vaccination strategy that reduces COVID-19 mortality the most as a function of T and ψ_0 (left) and the corresponding posterior parameter distributions for the refitted parameters (right). Other parameter values as in Table S1.





Fig. S22. Sensitivity analysis for the scenario of one-fourth the baseline social learning rate from December 2020 onward. Subpanels are parameter planes for January and September availability showing the vaccination strategy that reduces COVID-19 mortality the most as a function of T and ψ_0 . Other parameter values as in Table S1.

Vaccine available: Jan 1, 2021



Vaccine available: Sep 1, 2021




Fig. S23. Sensitivity analysis for the scenario where efficacy against disease v^D is not the same as efficacy against transmission v^T . Subpanels show percentage reduction in mortality for the four strategies versus v^D when $v^T = 0.75$ but v^D ranges from 0.75 to 0.95, for January and September availability. Other parameter values as in Table S1. Note that mortality in this plot is computed from March 15, 2020 to March 14, 2025.




Fig. S24. Posterior parameter distributions and model outputs for more stringent particle filtering criteria under Bayesian particle filtering algorithm. Top left panel shows (a) COVID-19 case incidence by date of report in Ontario, 7-day running average (circles) and ascertained case incidence from best fitting models (lines). (b) Percentage change from baseline in time spent at retail and recreation destinations (orange circles) and at workplaces (green circles) from Google mobility data, and proportion of the population x adhering to NPIs (orange line) and workplace shutdown curve (green line) from fitted model. Top right panel shows posterior parameter distribution for age-specific susceptibility modifier, ρ_i . Bottom panel shows other posterior parameter distributions. Other parameter values as in Appendix, pp. 1-11.




Fig. S25. Sensitivity analysis for more stringent particle filtering criteria under Bayesian particle filtering algorithm. Subpanels are parameter planes for January and September availability showing the vaccination strategy that reduces COVID-19 mortality the most as a function of T and ψ_0 (left) and violin plots showing percentage reduction in mortality (right). Horizontal lines represent median values of posterior model projections. Shutdown threshold $T=200\%$ and other parameter values in Appendix, pp. 1-11. Percentage reductions are relative to no vaccination. Projected number of deaths in the absence of vaccination was 72,000 (95% credible interval: 40,000 to 122,000) from January 1, 2021 to March 14, 2025 for (a) and 60,000 (95% credible interval: 31,000 to 108,000) from September 1, 2021 to March 14, 2025 for (b). Ontario Population size: 14.6 million.




Fig. S26. Model fit to data and baseline projections of mortality reductions under the four vaccine strategies, when behaviour is held constant over time. Top left: a) COVID-19 case incidence by date of report in Ontario, 7-day running average (circles) and ascertained case incidence from best fitting models (lines). (b) Percentage change from baseline in time spent at retail and recreation destinations (orange circles) and at workplaces (green circles) from Google mobility data, and proportion of the population x adhering to NPIs (orange line) and workplace shutdown curve (green line) from fitted model. Bottom left: Violin plots of the percent reduction in mortality under the four vaccine strategies, relative to no vaccination, as a function of the vaccination rate θ , for (a) January and (b) September 2021 availability. Horizontal lines represent median values of posterior model projections. Shutdown threshold $T=200\%$. Percentage reductions are relative to no vaccination. Projected number of deaths in the absence of vaccination was 72,000 (95% credible interval: 40,000 to 122,000) from January 1, 2021 to March 14, 2025 for (a) and 60,000 (95% credible interval: 31,000 to 108,000) from September 1, 2021 to March 14, 2025 for (b). Ontario Population size: 14.6 million. Right: Each parameter combination on the plane is colour coded according to which of the four strategies prevented the most deaths, on average across all model realizations, for (a) January and (b) September 2021 availability. Other parameter values in Appendix, pp. 1-11.




Fig. S27. Epidemic dynamics and social dynamics for both NPI adherence and vaccinating behaviour, when behaviour is held constant over time. (a) Ascertained incident COVID-19 cases, (b) proportion x of the population practicing NPIs, (c) Intensity of school and workplace closure, (d) percentage of population with natural or vaccine-derived immunity versus time. $T = 200\%$, $\psi_0 = 0.5\%$ per week, vaccine available in January 2021. Other parameters are in Table S1.

139 **Supplementary Appendix References**

140 1. CT Bauch, Imitation dynamics predict vaccinating behaviour. *Proc. Royal Soc. B: Biol. Sci.* **272**,
141 1669–1675 (2005).

142 2. C Innes, M Anand, CT Bauch, The impact of human-environment interactions on the stability of
143 forest-grassland mosaic ecosystems. *Sci. reports* **3**, 1–10 (2013).

144 3. VA Thampi, M Anand, CT Bauch, Socio-ecological dynamics of caribbean coral reef ecosystems and
145 conservation opinion propagation. *Sci. reports* **8**, 1–11 (2018).

146 4. CT Bauch, S Bhattacharyya, Evolutionary game theory and social learning can determine how vaccine
147 scares unfold. *PLoS Comput. Biol* **8**, e1002452 (2012).

148 5. T Oraby, V Thampi, CT Bauch, The influence of social norms on the dynamics of vaccinating behaviour
149 for paediatric infectious diseases. *Proc. Royal Soc. B: Biol. Sci.* **281**, 20133172 (2014).

150 6. E Zagheni, et al., Using time-use data to parameterize models for the spread of close-contact infectious
151 diseases. *Am. journal epidemiology* **168**, 1082–1090 (2008).

152 7. Y Li, et al., The temporal association of introducing and lifting non-pharmaceutical interventions with
153 the time-varying reproduction number (r) of sars-cov-2: a modelling study across 131 countries. *The*
154 *Lancet Infect. Dis.* (2020).

155 8. O Diekmann, J Heesterbeek, MG Roberts, The construction of next-generation matrices for compart-
156 mental epidemic models. *J. Royal Soc. Interface* **7**, 873–885 (2010).

157 9. H Nishiura, NM Linton, AR Akhmetzhanov, Serial interval of novel coronavirus (COVID-19) infections.
158 *Int. journal infectious diseases* (2020).

159 10. SA Lauer, et al., The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported
160 confirmed cases: estimation and application. *Annals internal medicine* (2020).

161 11. L Tindale, et al., Transmission interval estimates suggest pre-symptomatic spread of COVID-19.
162 *medRxiv* (2020).

163 12. Ontario Agency for Health Protection and Promotion (Public Health Ontario), COVID-19 case
164 fatality, case identification, and attack rates in ontario (<https://www.publichealthontario.ca/-/media/documents/ncov/epi/2020/06/COVID19-epi-case-identification-age-only-template.pdf?la=en>)
165 (2020).

166 13. Google, Inc., COVID-19 community mobility reports (2020) Available at <https://www.google.com/{COVID}19/mobility/>.

167 14. Treasury Board Secretariat of Ontario, Confirmed positive cases of COVID-19 in Ontario (2020)
168 Available at <https://data.ontario.ca/dataset/confirmed-positive-cases-of-{COVID}-19-in-ontario/resource/455fd63b-603d-4608-8216-7d8647f43350>.

169 15. Public Health Ontario, Covid-19 serosurveillance summary: Covid-19 seroprevalence in ontario: March
170 27, 2020 to june 30, 2020 (2020).

171 16. BM Turner, PB Sederberg, Approximate Bayesian computation with differential evolution. *J. Math.*
172 *Psychol.* **56**, 375–385 (2012).

173 17. F Allemanno, Kissabc.jl (<https://github.com/JuliaApproxInference/KissABC.jl>) (2020).

174 18. AA Malik, SM McFadden, J Elharake, SB Omer, Determinants of covid-19 vaccine acceptance in the
175 us. *EClinicalMedicine* **26**, 100495 (2020).

176 19. Statistics Canada, Census profile, 2016 census, <https://www12.statcan.gc.ca/>, accessed 25 september
177 2020 (2020).

178 20. K Prem, et al., Projecting contact matrices in 177 geographical regions: an update and comparison
179 with empirical data for the COVID-19 era. *medRxiv* (2020).

180 21. J Hilton, MJ Keeling, Estimation of country-level basic reproductive ratios for novel coronavirus
181 (COVID-19) using synthetic contact matrices. *medRxiv* (2020).

182 22. K Mizumoto, K Kagaya, A Zarebski, G Chowell, Estimating the asymptomatic proportion of coronavirus
183 disease 2019 (COVID-19) cases on board the diamond princess cruise ship, yokohama, japan, 2020.
184 *Eurosurveillance* **25**, 2000180 (2020).

185 23. WH Organization, Who target product profiles for COVID-19 vaccines, [https://www.who.int/who-](https://www.who.int/who-documents-detailredirect/who-target-product-profiles-for-COVID-19-vaccines)
186 documents-detailredirect/ who-target-product-profiles-for-COVID-19-vaccines, accessed 25 september
187
188
189

- 190 2020 (2020).
- 191 24. Globalnews Canada, Coronavirus: All publicly funded schools in ontario closing for 2 weeks due to
192 COVID-19. (2020) <https://globalnews.ca/news/6668240/coronavirus-ontario-schools-closed/>.
- 193 25. Globalnews, The dates and staggered starts for all GTA schools. (2020) <https://globalnews.ca/news/6668240/coronavirus-ontario-schools-closed/>.
- 194
- 195 26. Provincial government of Ontario, Canada, Reopening ontario in stages (2020) Available at <https://www.ontario.ca/page/reopening-ontario-stages>.
- 196